Uroplasty (UPI) vs. Its Peers Critical Analysis
Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Uroplasty to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk.
This is a summary of recent ratings and recommmendations for Uroplasty and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Uroplasty has a beta of -1.26, suggesting that its stock price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s peers have a beta of 0.47, suggesting that their average stock price is 53% less volatile than the S&P 500.
Earnings & Valuation
This table compares Uroplasty and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Uroplasty Competitors||$1.67 billion||$207.58 million||86.22|
Uroplasty’s peers have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Uroplasty and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Uroplasty peers beat Uroplasty on 6 of the 8 factors compared.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.